The Vanguard Group, Inc. recently announced the acquisition of new stake in NantHealth Inc. (NASDAQ:NH). The institutional investor has increased its shareholding in the Healthcare company by 16.27% to 1.29 million shares with purchase of 0.18 million shares. This fresh investment now brings its stake to 1.17% valued currently at $5.91 million. In addition, Renaissance Technologies LLC raised its holdings by 0.13 million to 0.65 million shares. And Miracle Mile Advisors LLC has lifted its position by 616.07% or 0.34 million shares – to 0.4 million shares.
With over 0.34 million NantHealth Inc. (NH) shares trading Friday and a closing price of $4.97 on the day, the dollar volume was approximately $1.69 million. The shares have shown a negative weekly performance of -4.61% and its price on 07/17/20 gained nearly 6.88%. Currently, there are 110.62M common shares owned by the public and among those 44.31M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for NH have a consensus price objective of $3.30. The analysts have set the share’s price value over the next 12 months at a high of $3.50 and a low of $3.10 should the stock experience a downside. The average price target is -50.61% below its last price level and a downside to the estimated low will see the stock lose -60.32% over that period. But an upside of -42.0% will see the stock hit the forecast high price target while mean target price for the stock is $3.30.
Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 304,753 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 5,055,962 shares.
The top 3 mutual fund holders in NantHealth Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.78 million shares of the company’s stock, all valued at over $3.58 million. The company sold -0.49 million shares recently to bring their total holdings to about 0.71% of the shares outstanding. iShares Russell 2000 ETF sold 13803.0 shares to see its total holdings shrink to 0.54 million shares valued at over $2.49 million and representing 0.49% of the shares outstanding. Vanguard Extended Market Index Fu sold 31400.0 shares to bring its total holdings to over 0.34 million shares at a value of $1.57 million. Vanguard Extended Market Index Fu now owns shares totaling to 0.31% of the shares outstanding.
Shares of NantHealth Inc. (NASDAQ: NH) opened at $4.65, unchanged from a prior closing price of $4.65. However, the script later closed the day at $4.97, up 6.88%. The company’s stock has a 5-day price change of -4.61% and 144.83% over the past three months. NH shares are trading 382.52% year to date (YTD), with the 12-month market performance up to 799.71% higher. It has a 12-month low price of $0.45 and touched a high of $6.39 over the same period. Currently, 0.34 million shares have been traded, compared to an average intraday trading volume of 687.14K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.63%, 41.96%, and 161.52% respectively.
Institutional ownership of NantHealth Inc. (NASDAQ: NH) shares accounts for 19.60% of the company’s 110.62M shares outstanding. Mutual fund holders own 2.55%, while other institutional holders and individual stakeholders account for 89.30% and 10.54% respectively.
It has a market capitalization of $514.39M and a beta (3y monthly) value of 1.98. The earnings-per-share (ttm) stands at -$0.47. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.06% over the week and 14.22% over the month.
Analysts forecast that NantHealth Inc. (NH) will achieve an EPS of -$0.05 for the current quarter, -$0.06 for the next quarter and -$0.18 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.06 while analysts give the company a high EPS estimate of -$0.05. Comparatively, EPS for the current quarter was -$0.04 a year ago. Earnings per share for the fiscal year are expected to increase by 67.50%, and 21.70% over the next financial year.
Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NH, a number of firms have released research notes about the stock. Canaccord Genuity stated their Buy rating for the stock in a research note on November 17, 2017, with the firm’s price target at $6-$5. Jefferies coverage for the NantHealth Inc. (NH) stock in a research note released on June 27, 2016 offered a Buy rating with a price target of. First Analysis Sec was of a view on June 27, 2016 that the stock is Overweight, while FBR Capital gave the stock Outperform rating on June 27, 2016, issuing a price target of $18.